ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
Article Jun 17, 2016
Brukers Innovative timsTOF™ Mass Spectrometer Unique Trapped Ion Mobility Spectrometry (TIMS) Coupled to Bruker’s High-Performance QTOF Mass Enables High-Resolution Compound Separation, Significant Duty Cycle Enhancements and Studies of Protein Conformations, Aggregation and Structural Isomers.
" timsTOF™ - Flexibility to Empower Your Ideas"
Dr. Dietrich Hauffe, EVP, Business Area Life Science Mass Spectrometry at Bruker Daltonics
The new Xevo TQ-XS mass spectrometer is the most sensitive benchtop tandem quadrupole instrument available. Enabled by the StepWave™ XS ion guide, this mass spectrometry system features a unique combination of ion optics, detection and ionization technologies resulting in levels of sensitivity not previously seen in quantitative mass spectrometry analysis.
" With this new mass spectrometer, our product designers pioneered some ingenious electronic and mechanical advances, leading to new levels of reliability, reproducibility, and performance."
Gary Harland, Senior Director MS Product Management
An overarching theme echoed by leading manufacturers of the instruments introduced at this year’s annual meeting of the American Society of Mass Spectrometry (ASMS) was notable for the dichotomy it represented: the evolution toward increasingly easy to use, hands-off MS systems that also continue to increase in technological complexity.
From June 5-9, in San Antonio, Texas, oral sessions, workshops, and poster presentations highlighted the expanding application range of MS in life sciences, food, energy, and health sciences research. The rapid adoption of MS in biomedical research has focused largely in the area of proteomics and metabolomics, biomarker identification, and drug discovery and development. Even as the leading vendors touted the sophisticated and unique capabilities of their newest technologies and products, and the novel types of applications they are enabling, their comments at ASMS underscored a shared goal:
MS should be a mainstream analytical research (and, in the not-too-distant future, routine clinical) tool that requires little to no special skills to perform.
The big picture that emerged from the scope of presentations was clear: the samples being analyzed, the questions being asked, the MS techniques being applied, and the ionization, detection, data acquisition, and other technology housed in the sleek boxes are all becoming more complex. In parallel, however, advanced software is being developed to create more user-friendly, fully integrated, and automated systems. The software is having an impact across the MS workflow – upstream to automate system set-up and calibration, sample preparation, and method development; and downstream to simplify data analysis and interpretation and results reporting.
“In the last 5-10 years, we have seen rapid acceleration of accurate mass technology, in the form of both GC-MS and LC-MS. Over the last 2-3 years the software, the workflow, is starting to catch up,” and “to unlock the power of the data,” Jim Yano, vice president of marketing, Mass Spectrometry Division at Agilent Technologies, tells us.
It’s About the Mass and the Masses
Ease of use and simplicity, combined with improved precision, reliability, robustness, and cost efficiency were common descriptors used by companies at ASMS. Whether they are developing integrated chromatography-MS systems for high throughput routine applications in analytical laboratories or meeting the growing need for high resolution accurate mass (HRAM) instruments in the research sector. Mark Roberts, product manager for Waters’ new Xevo® TQ-XS mass spectrometer, notes that more and more MS users have little experience with the technology. They tend to be technicians with Bachelor’s or Master’s degrees rather than Ph.D.’s with MS training. Thus, in designing the Xevo TQ-XS, Waters emphasized greater ease of use, combined with high throughput and features that would minimize downtime to improve productivity.
Thermo Fisher Scientific set out to make its Orbitrap MS technology more user-friendly for biotherapeutics applications, so it added a third scan mode and BioPharma software to create the all-in-one Q Exactive™ BioPharma MS/MS Hybrid Quadrupole-Orbitrap MS system. The Q Exactive BioPharma combines three protein characterization workflows in one instrument, says Jonathan Josephs, Ph.D., director of Marketing, Pharma/BioPharma, Life Sciences MS. These are intact protein analysis (e.g., for profiling antibody glycoforms in their native state); subunit and top-down analysis, with isotopic resolution; and peptide mapping of trypsin digests. Thermo Fisher extended the mass range of the new Q Exactive, enabling native MS analysis of therapeutic antibodies. The ability to perform structural analysis and monitor glycan changes is becoming increasingly important from a regulatory perspective to demonstrate consistent processes and products over time, according to Dr. Josephs.
Thermo Fisher also showcased 908 Devices’ ZipChip™ microfluidic capillary electrophoresis-based separation device that attaches to the front of its Orbitrap mass spectrometers. With no sample prep required, operators can load sub-microliter sample volumes into the chip-based device, which uses electrospray ionization (ESI) to deliver the sample directly off the chip into the mass spectrometer.
Advances in ion mobility technology were on display at ASMS. Bruker launched the timsTOF™ MS, featuring Trapped Ion Mobility Spectrometry (TIMS) coupled to the company’s high performance QTOF instrument. TIMS provides ion mobility resolution >200 to improve the separation of isomeric compounds and the accuracy of collisional cross section (CCS) data, and to support studies of protein conformation and aggregation. TIMS can resolve two species that differ by <1.0% in mobility. It controls ion movement through two mechanisms: gas flow that pushes ions in one direction; and an electric field that acts in the opposite direction, trapping the ions.
Frank Laukien, PhD, President and CEO of Bruker, called attention to the Ion Mobility Expansion (imeX™) feature of TIMS and its value for analyzing complex mixtures, such as in metabolomics research. This feature allows users to adjust the ion mobility resolving power to meet research or analytical needs.
Christian Bleiholder, Ph.D., Assistant Professor, Florida State University, referred to TIMS as “more of a structural elucidation technique than a separation technique.” He described its use to screen Alzheimer’s disease drug candidates for their ability to eliminate the fibrillar oligomers that comprise amyloid lesions in brain tissue.
Dietrich Hauffe, Ph.D., executive vice president, Business Area Life Science Mass Spectrometry, at Bruker told us that TIMS evolved out of the company’s research group based on the needs of customers working in diverse areas, including polymer analysis, therapeutic drug development, and high throughput proteomics. The emphasis was on combining acquisition of accurate mass measurements and CCS values to obtain structural information, and capturing all of the ions generated.
“We’re already taking the technology to the next level,” says Hauffe, and looking at “how we can manipulate ions going through TIMS.” Bruker is also exploring the use of TIMS with whole cells as well as potential clinical applications.
The ion mobility technology within Waters’ Xevo TQ-XS instrument gives it the ability to resolve co-eluting isomeric metabolites. The Xevo TQ-XS uses Waters’ T-wave technology to move ions through the system and incorporates the newly designed StepWave™ XS technology, which generates a smaller, more focused ion beam that yields 2x-10x increased sensitivity depending on the analyte. The addition of horizontal plates to the StepWave design creates a shallower voltage gradient, promoting broader ion capture from the gas flow into the mass analyzer. Waters also extended the dynamic range of the XDR detector used in the Xevo TQ-XS to avoid saturation with high concentration analytes, and added tool-free probes on the ESI and APCI ion sources. Finally, this new member of the Xevo product family has a faster analysis speed at 500 transitions per second.
UniSpray provides improved sensitivity for 10 μg/kg fenpropimorph in green tea allowing for increased flexibility to dilute matrix without impacting analyte detection.
Introduced as an option for the Xevo TQ-XS was Waters’ new UniSpray™ ion source. The UniSpray unit can be mounted onto the mass spec in place of the standard ion source, providing multiple ionization mechanisms suitable for different MS methods without having to change ion sources. You want to “ionize as much as possible in a single pass” to ensure you are seeing everything, says Ed Sprake; to “expand chemical space” and “cover more polarity.”
“More and more it is becoming about software to drive the next wave of innovation and to make sense of all the data,” says Jim Yano of Agilent. A host of new and recent software launches showcased by Agilent at ASMS support this statement. These include MassHunter VistaFlux Software for qualitative flux analytical workflow, and MassHunter Profinder Software, designed for data analysis from LC or GC quadrupole time-of-flight MS systems.
ICP-MS MassHunter software simplifies the workflow and automates method development on the 8900 Triple Quadrupole ICP-MS system, which Agilent introduced at ASMS. Shane Elliott, director of marketing, Atomic Spectroscopy at Agilent highlights the advantages of the instrument’s controlled reaction chemistry and low detection limits, in particular for identifying difficult to detect elements such as sulfur, phosphorus, and silicon. The low detection limits and fast detector speed also enable the 8900 ICP-MS to characterize nanoparticles in complex biological samples as low as sub-50 nm scale.
Agilent also introduced the JetClean Self-Cleaning Ion Source for its quadrupole GC-MS systems. The JetClean uses a controlled hydrogen flow to keep the ion source free of matrix deposits that can degrade performance over time.
Thermo Fisher expanded its cloud computing platform to enable a range of new functions, including monitoring of instrument performance, integration of multi-omics data, and development of routine workflows incorporating online content and allowing users to track, interrogate, and mine data across multiple instruments and labs. Among the company’s software launches at ASMS were BioPharma Finder™ for analysis of peptide digests and intact proteins, updated mzCloud™ Advanced Mass Spectral Database, and Sample Profiler, which helps users build their own product profile of known and unknown components.
MS for Industrial Scale Proteomics
Mass spectrometers and associated informatics tools are making the leap from the basic to the clinical research arena to drive precision medicine. Much of the early work has focused on cancer, using MS technology to refine cancer diagnosis and staging, guide treatment decisions, predict drug responsiveness, and monitor therapy and disease progression.
As an example, SCIEX presented its Next-Generation Proteomics (NGP) platform based on the company’s Triple TOF® 6600 MS system. The NGP platform includes new sample prep automation optimized for the Beckman Coulter Biomek® NX as well as Microflow SWATH® Acquisition software.
At the SCIEX media event, Phil Robinson, Ph.D., head of the Cell Signaling Unit at the Australia-based Children’s Medical Research Institute, described ProCan™. The ProCanTM project, underway at the Australian Cancer Research Foundation’s Center for the Proteome of Human Cancer, utilizes industrial scale proteomics, incorporating PCT-SWATH, to quantify thousands of proteins in about 70,000 tumors. Here tissue/tumor samples (0.2-1 mg) are liquefied, followed by microflow delivery for MS analysis. Data are available within 24-36 hours and are made publically available on OpenSWATH, a proteomics software supported by ETHZürich for analysis of (data independent acquisition) LC-MS/MS data.
SCIEX also announced the release of BIOPharmaView™ Software 2.0 for biotherapeutic data processing. Updates enable faster processing, the ability to process SWATH Acquisition data, automated drug-to-antibody ratio calculations for antibody drug conjugates, and automated PTM ratio calculations.
Speeding Up MS Analysis
Designed for analytical labs requiring a fast, robust, and cost-effective system to perform routine quantitative analyses, Shimadzu's new LCMS-8045 features a scan speed of 30,000 υ/sec, a polarity switching time of 5msec, and a heated electrospray ionization (ESI) source.
In introducing Shimadzu’s Clinical Laboratory Automation Module, the CLAM-2000, Brian Feild, biotech product manager, noted that the new sample preparation system is fully integrated with the LC-MS system and needs minimal operator input. “Even robotic systems require a lot of expertise to integrate,” said Mr. Feild. Users load samples into the CLAM-2000 and select a method; it completes sample pretreatment and delivers the samples directly to the LC-MS system. Sample processing time upstream of LC-MS is about 6 minutes.
Many of the advances on display at ASMS come in response to the industry’s need for load-and-go, plug-and-play MS systems for routine use. Analytical laboratories are seeking increasingly high throughput, reliable instruments that can churn out accurate results with minimal user expertise or input. Software-driven data analysis and reporting of results removes a large time and labor burden downstream. Continued innovation in HRAM technology will continue to drive research advances in proteomics, metabolomics, and drug development.
Vicki Glaser is a freelance writer living in Pennsylvania.
Phenotypic versus Target-based Screening for Drug DiscoveryArticle
Target-based screening has been the method of choice in drug discovery for the past two decades, but phenotypic screening is having something of a renaissance. We look at the advantages and applications of both.READ MORE
Relaxing the Tension Between Publishing and Patenting: Practical Hints and TipsArticle
In Part 1 we outlined some patent-related ramifications of publishing your research and development prior to filing a patent application. This second part provides you with some practical hints and tips for drafting your paper, helping you to avoid potential issues that can arise.READ MORE
Relaxing the Tension Between Publishing and Patenting: The Legal Basis for TensionArticle
Tension can be felt between the desire to publish and the need to patent, especially in commercially savvy environments such as medical technology and pharmaceuticals. This article discusses the legal rationale behind why publishing early can hinder future patenting opportunities and provides practical tips for avoiding this situation.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Structural and Molecular Biology 2018
Aug 22 - Aug 23, 2018
Asia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018